To Boost Or Not To Boost? Pfizer, FDA, And The COVID Vaccine Communication Challenge
Pfizer’s bid for third dose appears to get pushback from the US government, but reticence about the booster may reflect PR considerations more than any fundamental concern about the vaccine.
You may also be interested in...
Departures of Marion Gruber and Philip Krause may stem from White House and CDC actions related to the COVID-19 vaccines.
Reports indicate a 13 August CDC advisory committee meeting may be used to address an amended FDA emergency use authorization to allow immunosuppressed Americans to get additional COVID-19 vaccine doses. Such a move would not run afoul of the World Health Organization’s plea for a moratorium on boosters in the general population until much of the world initially can be vaccinated.
The company raised revenue guidance for its COVID-19 vaccine this year to a staggering $33bn from a prior estimate of $26bn.